HSDT - Helius Medical Technologies EV/EBITDA Multiple
Helius Medical (HSDT) produces equipment for traumatic brain injury therapy, the demand for which is independent of economic fluctuations and seasonality. The business relies on the creation of wearable neuromodulation systems, where macro factors only influence expansion rates and insurance coverage. This price chart shows that Helius Medical (HSDT) shares demonstrate an EV/EBITDA of 0.00. Management is currently focused on restructuring the commercial approach and crisis management.
Comprehensive metric breakdowns and analytics for heliusmedical.com (HSDT)
- market price and analyst price targets:
- market capitalization statistics:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Helius Medical|HSDT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Helius Medical Technologies|HSDT - Company Total Debt|Debts to Book Capitalization Helius Medical Technologies, Inc.|HSDT - Long-Term Debt|Company Short-Term Debts Helius Medical Technologies|Quick Ratio heliusmedical.com
- net income and valuation multiples indicators:
HSDT - Net Financial Result|Projected Future Earnings Helius Medical|HSDT - Price to Earnings Ratio|Forward P/E Multiple Helius Medical Technologies|HSDT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Helius Medical Technologies, Inc.|HSDT - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Helius Medical Technologies|HSDT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months heliusmedical.com|HSDT - Expected net earnings per share growth this year|Earnings growth forecast for next year Helius Medical
Analysis of all company metrics:Helius Medical Technologies Inc. HSDT
Helius Medical (HSDT) maintains its leadership in the neuromodulation therapy niche, allocating significant resources toward the development of the PoNS AI platform. The ratio of total enterprise value to operating profit, reflected through the EV/EBITDA multiple, allows for a comparison of market capitalization, including debt, against the actual efficiency of capital-intensive R&D assets, identifying optimal entry points during price corrections.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|Xenon Pharmaceuticals Inc. (XENE) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN - Enterprise Value to EBITDA Ratio|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|PRAX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ALEC|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VYGR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NMRA: EV/EBITDA Multiple|Scilex Holding Company, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|Inhibikase Therapeutics Inc - Enterprise Value to Operating Income Before Depreciation|Cassava - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ASRT (Assertio Holdings)|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VTGN (Vistagen Therapeutics) - Enterprise Value to Operating Income Before Depreciation|OVID: EV/EBITDA Multiple|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to EBITDA Ratio CRVO|EV/EBITDA Multiple Alterity Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|PEPG (pepgen.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Relmada Therapeutics Inc (RLMD) - Company Value to EBITDA|Annovis Bio Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRCE (Grace Therapeutics, Inc.)|AIFF: EV/EBITDA Multiple|Company Value to EBITDA Klotho Neurosciences (KLTO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RVPH|EV/EBITDA Multiple MTVA|Total Company Value to Operating Income Before Depreciation Ratio NeurAxis Inc|Passage Bio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neuphoria Therapeutics, Inc. NEUP|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Inc ATHA|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Alzamend Neuro - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to EBITDA Ratio Protagenic (PTIX)|EV/EBITDA Multiple KTTA|CRGT - Company Value to EBITDA|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|BCLI: Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Marinus Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRBO (neurobopharma.com)|EV/EBITDA Multiple SAGE (Sage Therapeutics)|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Vigil Neuroscience VIGL|WENA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CERE
